JP2023548973A - 膜タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 - Google Patents

膜タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 Download PDF

Info

Publication number
JP2023548973A
JP2023548973A JP2023552149A JP2023552149A JP2023548973A JP 2023548973 A JP2023548973 A JP 2023548973A JP 2023552149 A JP2023552149 A JP 2023552149A JP 2023552149 A JP2023552149 A JP 2023552149A JP 2023548973 A JP2023548973 A JP 2023548973A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
disease
seq
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548973A5 (enExample
Inventor
ローブ，アンドレアス
ダブリュ． ホール，サミュエル
Original Assignee
フラックス セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラックス セラピューティクス，インコーポレイテッド filed Critical フラックス セラピューティクス，インコーポレイテッド
Publication of JP2023548973A publication Critical patent/JP2023548973A/ja
Publication of JP2023548973A5 publication Critical patent/JP2023548973A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023552149A 2020-11-06 2021-11-05 膜タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 Pending JP2023548973A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110619P 2020-11-06 2020-11-06
US63/110,619 2020-11-06
PCT/US2021/058291 WO2022099038A1 (en) 2020-11-06 2021-11-05 Membrane protein targeting engineered deubiquitinases and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023548973A true JP2023548973A (ja) 2023-11-21
JP2023548973A5 JP2023548973A5 (enExample) 2024-11-12

Family

ID=81456825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552149A Pending JP2023548973A (ja) 2020-11-06 2021-11-05 膜タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法

Country Status (7)

Country Link
US (1) US20240002473A1 (enExample)
EP (1) EP4240754A4 (enExample)
JP (1) JP2023548973A (enExample)
CN (1) CN116802198A (enExample)
AU (1) AU2021373873A1 (enExample)
CA (1) CA3200983A1 (enExample)
WO (1) WO2022099038A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121471382A (zh) * 2026-01-12 2026-02-06 合肥综合性国家科学中心大健康研究院 去泛素化酶Fc融合蛋白及其产品、制备方法和在苗头化合物筛选中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200263159A1 (en) * 2017-11-06 2020-08-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101671688A (zh) * 2009-09-25 2010-03-17 上海大学 EGFP融合的β2肾上腺素能受体、其重组表达载体及其构建方法
US20210079366A1 (en) * 2017-12-22 2021-03-18 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200263159A1 (en) * 2017-11-06 2020-08-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes

Also Published As

Publication number Publication date
EP4240754A4 (en) 2024-09-04
US20240002473A1 (en) 2024-01-04
CN116802198A (zh) 2023-09-22
CA3200983A1 (en) 2022-05-12
AU2021373873A1 (en) 2023-06-08
AU2021373873A9 (en) 2024-08-01
WO2022099038A1 (en) 2022-05-12
EP4240754A1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
KR102159109B1 (ko) 항 ｉｌ-36ｒ 항체
KR101720394B1 (ko) 친화성 복합체에 대한 항체
CN105555803B (zh) 制瘤素m受体抗原结合蛋白
JP2020514277A (ja) プログラム死リガンド−１（ｐｄ−ｌ１）に結合する抗体を使用する免疫
TW202346354A (zh) 抗ceacam5抗體及其結合物及用途
CN121038815A (zh) 半乳糖缺陷型免疫球蛋白的双功能降解剂
WO2018087143A2 (en) Anti-pd-1 antibodies
JP2023549761A (ja) 核タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法
JP2023548973A (ja) 膜タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法
JP2023549167A (ja) ミトコンドリアタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法
CN103596984B (zh) 抗-人epo受体的抗体及使用方法
WO2022093641A1 (en) Anti-nkg2a agents and compositions and methods for making and using the same
JP2023551068A (ja) サイトゾルタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法
WO2023108115A1 (en) Ph-selective antibody fc domains
EP4293046A1 (en) Anti-pd-1 antibody and use thereof
TW202513590A (zh) 與ｌｉｌｒｂ１結合的抗體或抗原結合片段及其用途
WO2025096542A2 (en) Clec2d binding proteins and related methods
WO2025210538A1 (en) Bifunctional degraders
JP2023542497A (ja) 抗セルロプラスミン抗体及びその使用
HK1193615B (en) Anti-human epo receptor antibodies and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406